Mara Goldstein
Stock Analyst at Mizuho
(0)
# 3300
Out of 5,243 analysts
89
Total ratings
26.53%
Success rate
2.33%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Verastem | Maintains: Outperform | 7 9 | 5.3 | 69.81% | 6 | Dec 19, 2024 | |
Kura Oncology | Maintains: Strong Buy | 26 32 | 7.2 | 344.44% | 2 | Jan 31, 2024 | |
Arcus Biosciences | Maintains: Buy | 51 42 | 14.24 | 194.94% | 4 | Jan 30, 2024 | |
Xencor | Maintains: Buy | 59 50 | 19.5 | 156.41% | 2 | Jan 22, 2024 | |
Syndax Pharmaceutica... | Initiates Coverage On: Buy | 45 | 12.79 | 251.84% | 1 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 82 77 | 72.61 | 6.05% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 8 7 | 1.96 | 257.14% | 3 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 12 8 | 1.34 | 497.01% | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 20 12 | 3.21 | 273.83% | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 30 | 5.92 | 406.76% | 4 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 6 | 0.92 | 552.17% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 4 | 5.02 | -30.28% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 40 30 | n/a | n/a | 3 | May 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 12 | 0.3 | 3900% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 10 20 | 1.96 | 920.41% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 130 | 100.13 | 29.83% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 4 2 | 0.83 | 140.96% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 20 2 | n/a | n/a | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 18 12 | 2.29 | 424.02% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 9 | 0.55 | 1536.36% | 3 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 500 | n/a | n/a | 1 | Oct 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 13 10 | n/a | n/a | 2 | Sep 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 96 | n/a | n/a | 4 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 14 20 | 47.53 | -57.92% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 34 48 | 6.72 | 614.29% | 4 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 135 45 | 22.95 | 96.08% | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 22800 6000 | n/a | n/a | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 12 14 | 5.46 | 156.41% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 15 9 | n/a | n/a | 1 | Sep 14, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 15 | n/a | n/a | 1 | Jul 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 16 6 | n/a | n/a | 2 | Apr 18, 2017 |